Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insider Analysis: The Glivec Patent Saga – Effectuating “Efficacious” Patent Norms In India

This article was originally published in PharmAsia News

Executive Summary

By: Shamnad Basheer

You may also be interested in...



Indian Pharma Lobby Calls For Re-examination Of 81 MNC Drug Patents

MUMBAI - As Indian companies battle multinational drug giants for patent rights, the Indian Pharmaceutical Alliance - an association that represents top Indian drug companies - wrote to the Union Ministry of Commerce and Industry Feb. 14 that a large number of pharmaceutical patents granted over the last four years are granted to new forms of known substances and combinations of old drugs

Indian Pharma Lobby Calls For Re-examination Of 81 MNC Drug Patents

MUMBAI - As Indian companies battle multinational drug giants for patent rights, the Indian Pharmaceutical Alliance - an association that represents top Indian drug companies - wrote to the Union Ministry of Commerce and Industry Feb. 14 that a large number of pharmaceutical patents granted over the last four years are granted to new forms of known substances and combinations of old drugs

As Novartis’ Glivec Hearing Approaches, Indian IP Panel Adds Court-Ordered Technical Member

NEW DELHI - Swiss pharma giant Novartis is "pleased" with the appointment of a new technical member to an Indian panel hearing a high-profile challenge by Novartis regarding the rejection of patent protection for its blockbuster leukemia drug Glivec

Related Content

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel